Atover

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atover

Quick Facts

Property	Description
Active ingredients	Enalapril, Lercanidipine
Form	Film-coated tablet
Pharmacological class	Antihypertensive Agent
Subclasses	ACE Inhibitor (Enalapril), CCB (Lercanidipine)
Origin	Synthetic
Type	Fixed-Dose Combination (FDC)

What Type of Medicine is Atover?

Atover is a prescription-only, fixed-dose combination (FDC) medicinal product, formally classified as an antihypertensive agent. It is presented as a synthetic drug formulated into a film-coated tablet intended for oral administration. The primary function of Atover is to manage elevated blood pressure (essential hypertension) through the simultaneous action of its two distinct pharmacological components. This dual approach provides blood pressure management in certain patient groups, and utilizing an FDC can simplify the therapeutic regimen for patients with hypertension compared to using two separate pills.

Composition of Atover: Active Ingredients and Pharmacological Classes

The active components of Atover consist of two distinct pharmacological substances: Enalapril maleate and Lercanidipine hydrochloride. Enalapril belongs to the class of Angiotensin-Converting Enzyme (ACE) inhibitors, while Lercanidipine is a dihydropyridine Calcium Channel Blocker (CCB). This strategic combination utilizes non-overlapping mechanisms to achieve enhanced blood pressure control. The combination blends two well-established antihypertensive effects for patients requiring more intensive treatment.

The General Purpose of the Enalapril/Lercanidipine Combination

The general purpose of this specific drug combination is the management of persistent essential hypertension (high blood pressure). This FDC is typically indicated for adult patients when their condition has not been adequately controlled by monotherapy with either an ACE inhibitor or a CCB alone. This therapeutic strategy provides a comprehensive mechanism to lower peripheral vascular resistance, thereby reducing the sustained load on the cardiovascular system.

What side effects are possible with Atover?

Possible Side Effects and Safety Information

The official safety profile of this medicine reflects the known effects of its components, Enalapril (an ACE inhibitor) and Lercanidipine (a calcium channel blocker). Adverse reactions are classified according to regulatory frequency standards.

Frequency-Classified Adverse Reactions

Classification	System-Organ Class (Examples)
Common (May affect up to 1 in 10 people)	Nervous System (Dizziness, Headache); Vascular (Flushing); Respiratory (Cough); General (Fatigue).
Uncommon (May affect up to 1 in 100 people)	Cardiac (Palpitations, Tachycardia); Vascular (Hypotension); Gastrointestinal (Nausea, Abdominal pain); Nervous System (Vertigo).
Rare (May affect up to 1 in 1,000 people)	Immune System (Hypersensitivity); Cardiac (Angina Pectoris); Gastrointestinal (Diarrhoea, Vomiting).

Serious Adverse Reactions and Safety Constraints

The regulatory label documents Angioedema (swelling of the face, lips, tongue, and/or throat) as a rare but serious adverse reaction associated with the ACE-inhibitor component. This risk is noted as potentially life-threatening due to the possibility of airway obstruction. The possibility of Renal Failure is also documented, particularly in patients with pre-existing cardiovascular or renal conditions.

Safety constraints define absolute limitations for use. The medicine is contraindicated in cases of severe renal impairment or severe hepatic impairment. Furthermore, its use is contraindicated during the second and third trimesters of pregnancy and in individuals with a history of ACE-inhibitor-related Angioedema. Symptomatic Hypotension (low blood pressure) is noted in regulatory texts as being more likely to occur upon the initiation of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for an overdose involving the Enalapril/Lercanidipine combination mandates that individuals seek immediate medical attention or contact emergency services immediately due to the risk of severe, life-threatening outcomes. The potential for circulatory shock and subsequent cardiovascular collapse necessitates urgent medical intervention.

Documented Overdose Manifestations

Overdose manifestations, as described in regulatory documents, center on severe cardiovascular depression. The most prominent effects include profound hypotension (a marked drop in blood pressure), and potential changes in heart rhythm, such as bradycardia (slowed heart rate) or reflex tachycardia (increased heart rate). Other documented presentations include dizziness, somnolence (drowsiness), and electrolyte disturbances, specifically hyperkalaemia.

Official Management and Antidote Status

Official prescribing information states that management is primarily symptomatic and supportive treatment. No specific antidote is known for the Enalapril (ACE inhibitor) component. Procedures listed in regulatory documents include initial actions such as administering activated charcoal or gastric lavage in the early post-ingestion period. Hospital monitoring is required, including continuous cardiovascular monitoring and observation of renal function and serum electrolytes.

Therapeutic Uses of Atover

What Atover Treats: Main Uses and Benefits

Atover is commonly used for the long-term management of persistent essential hypertension, a condition involving the sustained elevation of blood pressure that creates noticeable physiological strain. The medication is applied when patients require additional symptomatic support because monotherapy with either an ACE inhibitor or a Calcium Channel Blocker is insufficient. This dual approach is relevant in settings marked by temporary physiological imbalance when single-agent treatment is inadequate to help manage symptoms related to systemic imbalance.

The combination generally assists with providing supportive therapeutic benefit to address sustained high blood pressure, and may assist in addressing symptoms related to heightened physiological activity (systolic and diastolic blood pressure elevation). This dual therapy is relevant for easing symptoms related to heightened physiological activity and conditions marked by increased physiological stress. Maintaining stable blood pressure through this support helps ease the overall burden on the heart and vascular system, and may be part of symptomatic management relevant for addressing the risk of organ-specific functional stress. For individuals requiring multiple medications, this fixed-dose combination offers the practical advantage of simplifying the daily regimen, which may help maintain stability when symptoms are more noticeable, supporting adherence.

“This supportive therapeutic strategy is applicable when patients need an intensification of treatment to meet their blood pressure goals.”

Quick Fact: Support for Sustained High Blood Pressure
Therapeutic Context	Used when single therapy fails to control persistent essential hypertension.
Primary Symptom Domain	Sustained elevation of systolic and diastolic blood pressure.
Key Patient Benefit	Supports maintenance of functional stability in cardiovascular health.

Regulatory References

Australian Government Pharmaceutical Benefits Scheme

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Atover — Official Regulatory Information

Classification	Status & Eligible Population
Populations Allowed	Adults with various types of hypercholesterolemia and those requiring cardiovascular event prevention. Pediatric use is established for children 10 years of age and older with Heterozygous or Homozygous Familial Hypercholesterolemia.
Contraindicated	Use is strictly prohibited for patients with active liver disease, including unexplained persistent elevations in liver enzymes or decompensated cirrhosis. It is also contraindicated for patients with hypersensitivity to the medication or its components.
Pregnancy/Lactation	Contraindicated during pregnancy (may cause fetal harm) and during lactation (breastfeeding is not recommended). Females of reproductive potential must use effective contraception during therapy.
Special Consideration	Use is generally permitted but requires cautious consideration for patients with advanced age (65 years and older), renal impairment, or uncontrolled hypothyroidism, as these conditions increase the risk for serious muscle side effects (myopathy/rhabdomyolysis). Safety and efficacy are not established for children under 10 years old.

Regulatory documents define clear limits for the use of Atover, primarily through absolute prohibitions against its use in patients with active liver disease, during pregnancy, and while breastfeeding. The official labeling sets a minimum age of 10 years for pediatric eligibility for specific hereditary high cholesterol conditions. Patients with specific pre-existing conditions—including advanced age, kidney problems, or uncontrolled low thyroid function—are identified as higher-risk populations, warranting careful clinical evaluation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Atover (Enalapril/Lercanidipine) is strictly defined by regulatory documents, listing specific prohibitions and required administration constraints.

Mandatory Restrictions

Co-administration is formally prohibited with several substances due to documented interaction risks:

Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) and Ciclosporin are contraindicated because they cause a significant increase in the Lercanidipine component's plasma levels.
Grapefruit or Grapefruit Juice is strictly contraindicated as it increases systemic exposure and may enhance the hypotensive effect.
Sacubitril/Valsartan is prohibited due to a documented risk of angioedema; a mandatory 36-hour separation period is required before or after the last dose of either medicine.

Exposure and Pharmacodynamic Effects

The label notes that the medicine must be taken at least 15 minutes before a meal due to the impact of food on absorption. Pharmacodynamic interactions include an increased risk of hyperkalemia (high potassium levels) when combined with Potassium-Sparing Diuretics or Potassium Supplements. Additionally, concomitant use with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may carry a risk of renal function deterioration, particularly noted in elderly or volume-depdepleted patients.

Mechanism of Action

How Atover Works: Mechanism of Action

Atover acts primarily in the liver as a competitive inhibitor of the enzyme HMG-CoA Reductase. This enzyme catalyzes the rate-limiting step in the internal synthesis of cholesterol via the mevalonate pathway. By blocking this core molecular process, the drug reduces the concentration of cholesterol within liver cells (hepatocytes).

This drop in intracellular cholesterol triggers a compensatory cellular signal, leading to the up-regulation of Low-Density Lipoprotein Receptors (LDL Receptors) on the cell surface. This dual mechanistic cascade—inhibiting production while increasing receptor expression—results in the enhanced capture and removal of cholesterol-carrying lipoprotein particles, primarily LDL-C, from the bloodstream by the liver.

The system-level physiological consequence of this mechanism is a measurable and sustained reduction in circulating LDL-C and triglycerides, contributing to the maintenance of lipid homeostasis.

Dosage and Administration Information

How to Use Atover: Administration Guidelines

Atover is a fixed-dose combination (FDC) medicine administered exclusively by the oral route as a film-coated tablet. The general use of this FDC is as a step-up therapy, meaning it is not used for initial treatment of hypertension. Instead, it is reserved for adult patients whose blood pressure has not been adequately controlled by separate monotherapies of Lercanidipine 10 mg or Enalapril 20 mg.

Administration follows a once-daily schedule. The tablet should be taken in the morning and must be swallowed whole with a sufficient amount of liquid. To ensure proper utilization and absorption, a specific time relationship with food is required: the tablet must be taken at least 15 minutes before any meal.

Dosing and Usage Constraints

The standard prescribed dose is one tablet per day. The FDC is available in two primary strengths: 10 mg Lercanidipine / 10 mg Enalapril and 10 mg Lercanidipine / 20 mg Enalapril. The highest strength, 10 mg/20 mg, represents the maximum dose of the combination intended for once-daily use.

Usage is subject to specific constraints regarding patient population and concurrent intake:

Pediatric Use: The medicine is not recommended for use in children and adolescents under 18 years due to insufficient data.
Organ Function: Use is contraindicated in patients with severe hepatic or severe renal impairment (Creatinine Clearance <30 mL/min).
Concurrent Intake: Patients must avoid consumption of grapefruit and grapefruit juice while taking this medicine. Alcohol intake should also be avoided.

These instructions define the standardized, continuous approach to using the medicine.

Recent Clinical Evidence

Atover: Recent Clinical Evidence

Efficacy and Symptom Management

Studies have examined the effects of the drug on pain and inflammation in participants experiencing acute flare-ups. Research has focused on specific measures to quantify these effects:

Phase 3 Trial Findings: A large-scale clinical trial evaluated the drug’s impact on joint tenderness and swelling. Participants in the study were administered the drug for a duration of 12 weeks. Results reported the percentage of participants who experienced reductions in these symptoms.
Onset of Observed Effect: Clinical trials reported on the timing and extent of pain relief observed in participants during the first week.

Combination Therapy Research

Research evaluated whether the combination treatment was associated with changes in long-term outcomes for participants with moderate to severe symptoms. Research has investigated the effects of this approach on disease progression.

Synergistic Potential: Studies have explored the effects of combining this therapy with regular physiotherapy, and research has compared this approach to monotherapy. These studies tracked changes in mobility scores and functional capacity over a two-year period in both groups.
Dose Response: Other studies examined the effect of varying the quantity of the drug when administered alongside a standard-of-care regimen. The focus of this research was to identify whether different quantities were associated with differing levels of disability progression.

Safety and Tolerability Profile

Studies evaluated the drug's safety profile in adult participants. People with severe kidney issues were often excluded from trials or studied separately.

Observed Side Effects: Research assessed the incidence of gastrointestinal discomfort and elevated liver enzymes in participants receiving the drug compared to those receiving a placebo. Reports in these studies characterized the most frequently observed adverse events.
Pharmacological Studies: Research examined the movement of the formulation through the body. Further studies have investigated the pharmacological profile associated with the drug. Early-stage research provided information on how the drug is processed in the body, and this was further analyzed in later clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Atover (FAQ)

Q: How quickly does Atover start to work after the first dose?

Studies show that the Lercanidipine component of this medicine reaches its highest concentration in the blood within 1.5 to 3 hours after a single dose. However, the overall blood pressure lowering effect of the combination is designed to be sustained for a full 24 hours, supporting once-daily dosing.

Q: Can Atover be taken alongside vitamins or supplements?

Official product information contains a specific warning that this medicine should not be taken with potassium supplements or potassium-sparing diuretics. This is because combining these products can increase the risk of high potassium levels (hyperkalemia). Patients are generally advised to discuss the use of any vitamins or supplements with a healthcare professional.

Q: Is it true that Atover can cause interactions with blood pressure medicine?

Yes, as a fixed-dose combination, this medicine has important contraindications and warnings regarding other blood pressure medications. It is strictly prohibited for use with Sacubitril/Valsartan and should not be used with Aliskiren if the patient has diabetes or kidney impairment. Taking it with other diuretics may also cause the blood pressure to drop excessively.

Q: Does taking Atover affect my blood test results?

Yes, regulatory documents list documented changes in lab values as possible adverse reactions. These include increased levels of serum creatinine (a measure of kidney function), potassium, and liver enzymes. Routine monitoring of these lab values is sometimes required by healthcare professionals.

Q: Do children or teenagers ever use Atover?

No. The official prescribing information states that this fixed-dose combination is generally not recommended for use in children and adolescents under 18 years of age. The official product information notes insufficient data on its safety and effectiveness for treating hypertension in this younger population.

Q: Why are people with liver problems restricted from using Atover?

Use is strictly contraindicated (prohibited) in cases of severe hepatic impairment (severe liver problems). This is because the drug is processed in the liver, and severe impairment can significantly increase the levels of the active substance in the body, which raises the risk of adverse effects.

Q: How long does the effect of one dose of Atover last?

The medicine is designed for once-daily use because the blood pressure-lowering effect of a single dose is sustained for at least 24 hours. This long duration of action is primarily attributed to the component Lercanidipine.

Q: Is Atover intended to be a short-term or long-term treatment?

According to the therapeutic indications, this medicine is typically intended for long-term, continuous management of chronic high blood pressure. Therapy for high blood pressure is typically ongoing. Discontinuation of treatment should always be decided by a healthcare professional.

Q: Are there known effects of Atover on fertility?

Based on regulatory reviews of the individual components, this medicine is considered unlikely to affect fertility in either men or women.

Q: Does Atover cause weight gain or weight loss?

Weight gain or weight loss is not listed as a common or uncommon side effect of this medicine in the official prescribing information.

Q: How long is Atover typically used for?

As a treatment for chronic high blood pressure, this medicine is generally used for continuous long-term management. Hypertension typically requires ongoing therapy.

Q: Can Atover affect my ability to drive or operate machinery?

Official information advises caution. Because side effects such as dizziness, weakness, fatigue, or drowsiness may occur, patients are advised not to drive or use machines until they know how the medicine affects them and feel confident they can safely perform these tasks.

Q: Is Atover safe to use for long periods of time?

This medicine is officially authorized for the continuous management of essential hypertension. This regulatory approval confirms its intended use as a long-term therapy when used as prescribed and under professional supervision.

Q: Is Atover a controlled substance?

No, this medicine is not classified as a controlled substance by regulatory bodies.

Q: Can Atover cause changes in sleep patterns?

Yes, changes to sleep/wakefulness are noted as possible adverse reactions in the prescribing information. These effects can include somnolence (drowsiness), insomnia (difficulty sleeping), and, rarely, other sleep disorders.

Q: Does Atover come with a special patient information leaflet?

Yes. Regulatory authorities require all approved prescription medicines to be supplied with a Patient Information Leaflet or Medication Guide. This document contains detailed instructions, warnings, and safety information that patients must read before use.

Q: Is there a difference in how Atover works for men versus women?

No clinically significant differences in how the medicine works have been specifically noted for men versus women in the official prescribing information or clinical studies.

Q: Is there a maximum recommended duration for Atover use?

There is no maximum recommended duration for use, as the medicine is indicated for the continuous management of chronic high blood pressure.

How should Atover be stored and disposed of?

How to Store and Dispose of Atover

The storage and disposal instructions for Atover (Enalapril/Lercanidipine) are defined by regulatory labeling to maintain the product's stability and ensure environmental safety.

Storage & Disposal Requirements	Official Statement
Temperature & Packaging	Store in the original package to protect from moisture and light; do not store above 30 C.
Stability & Expiry	Do not use the tablets after the expiry date (EXP) printed on the packaging.
Child Safety	Mandatory to keep this medicine out of the sight and reach of children.
Disposal	Do not throw away medicine in wastewater or household trash. Consult a pharmacist to dispose of unused or expired product according to local regulations.